Centers | ||
Therapeutic Accelerator Program (TAP) | VMCC, University of Michigan | TEST |
Test |
The VMCC is an on-campus core facility for the design and synthesis of drug-like molecules and diagnostic probes used in biomedical investigations. Our Mission: To assist biomedical researchers in translating novel therapeutic hypotheses into... |
info here |
Partnerships |
Events |
Jobs |
Novo Nordisk and Oxford to Develop Drugs to Treat Rheumatoid Arthritis and Other Inflammatory DiseasesNovo Nordisk and Kennedy Institute of Rheumatology at Oxford University have entered into partnership to develop new drugs to treat Rheumatoid Arthritis and other inflammatory disorders. Novo Nordisk will provide research funding support to ten... View all Yale to Partner with Gilead to Further Cancer ResearchYale and Gilead have entered into a multi-year research collaboration to develop new treatments against cancer. Gilead will provide $40million in funding for research and other infrastructure support for the initial four years. The agreement can... View all Research Collaboration and license agreementThe Drug Discovery Unit announces a partnership with Takeda, Japan’s largest pharmaceutical company, to develop possible new therapeutic treatments for tau pathology, an underlying feature in several forms of neurodegeneration, including... View all |
No EVENTS for listing |
No Job Posts |


